Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BMS Forms Immuno-Oncology Network | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

BMS Forms Immuno-Oncology Network

II-ON covers 10 academic institutions

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Bristol-Myers Squibb has formed the International Immuno-Oncology Network (II-ON), a global collaboration between industry and academia intended to further the scientific understanding of immuno-oncology. Immuno-oncology focuses on the potential of harnessing the body’s immune system to fight cancer. In addition to BMS, the II-ON is currently comprised of ten leading cancer-research institutions, including:

  • Clinica Universidad Navarra, Pamplona, Spain
  • Dana-Farber Cancer Institute, Boston, MA
  • The Earle A. Chiles Research Institute (Providence Health & Services), Portland, OR
  • Institut Gustave Roussy, Villejuif, France
  • Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale,” Naples, Italy
  • Johns Hopkins Kimmel Cancer Center, Baltimore MD
  • Memorial Sloan-Kettering Cancer Center, New York, NY
  • The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK
  • The Netherlands Cancer Institute, Amsterdam, NL
  • The University of Chicago, Chicago, IL

The collaborative forum aims to facilitate the translation of scientific research findings into clinical trials and clinical practice, and will also work to further advance innovation in drug discovery and development.

“The International Immuno-Oncology Network facilitates a public-private partnership that will leverage intellectual capabilities across a global network,” said Elliott Sigal, M.D., Ph.D., executive vice president, chief scientific officer and president, R&D, BMS. “The shared commitment of all those participating in this collaboration is to evolve our understanding of immuno-oncology towards our ultimate goal of improving patient outcomes.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics